NCT02152943 - Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 17, 2014

Primary Completion Date

December 14, 2020

Study Completion Date

December 14, 2020

Conditions

Advanced Malignant Solid NeoplasmEstrogen Receptor PositiveHER2/Neu PositivePostmenopausalPremenopausalProgesterone Receptor PositiveRecurrent Breast CarcinomaRefractory Breast CarcinomaRefractory Hormone Receptor Positive Breast CarcinomaStage IIIA Breast Cancer AJCC v7Stage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7Stage IV Breast Cancer AJCC v6 and v7

Interventions

DRUG

Everolimus

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Letrozole

Given PO

BIOLOGICAL

Trastuzumab

Given IV

Trial Locations (5)

77030

M D Anderson Cancer Center, Houston

77058

MD Anderson League City, Nassau Bay

77094

MD Anderson in Katy, Houston

77384

MD Anderson in The Woodlands, The Woodlands

77478

MD Anderson in Sugar Land, Sugar Land

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER